New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
06:21 EDTREGNRegeneron shares attractive at current levels, says Citigroup
Citigroup expects sales of Eylea to rebound in Q2 and it finds shares of Regeneron attractive at current levels. Citi says the stock has been weak over the past two weeks amid concerns that use of Avastin will grow. After surveying 31 retinal specialists, Citi keeps a Buy rating on Regeneron with a $390 price target.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:51 EDTREGNBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:31 EDTREGNRegeneron price target raised to $462 from $418 at BofA/Merrill
Subscribe for More Information
November 20, 2014
07:47 EDTREGNRegeneron price target raised to $450 from $390 at Brean Capital
Subscribe for More Information
05:22 EDTREGNRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
08:17 EDTREGNRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
November 18, 2014
05:43 EDTREGNRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 12, 2014
08:13 EDTREGNBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use